{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T14:05:25Z","timestamp":1789740325539,"version":"4.0.1"},"reference-count":19,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T00:00:00Z","timestamp":1789689600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Cancer-associated thrombosis (CAT) is a major cause of morbidity and mortality in patients with malignancy and is increasingly recognized as a manifestation of tumor-associated thrombo-inflammation. Although immune checkpoint inhibitors (ICIs) have transformed the treatment of microsatellite instability-high (MSI-H) malignancies, their impact on the interplay between antitumor immunity and cancer-associated thrombosis remains poorly understood, particularly in intrahepatic cholangiocarcinoma (ICC).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>We report a 74-year-old woman with MSI-H intrahepatic cholangiocarcinoma presenting with Trousseau syndrome characterized by extensive arterial and venous thrombotic events, including deep vein thrombosis, portal vein thrombosis, multifocal cerebral infarctions, splenic infarction, and renal infarction. Following treatment with the PD-L1 inhibitor envafolimab in combination with rivaroxaban, radiographic evaluation demonstrated stable disease without recurrent thrombotic events. Longitudinal biomarker assessment revealed temporally associated reductions in circulating D-dimer and interleukin-6 (IL-6) concentrations during treatment, while peripheral immune-cell subsets exhibited dynamic changes that paralleled systemic inflammatory activity. Despite a temporary interruption of immunotherapy because of influenza A-associated pneumonia, both inflammatory and coagulation markers declined following resolution of the infection.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This case underscores the complex interplay between systemic inflammation, coagulation activation, and tumor progression in MSI-H intrahepatic cholangiocarcinoma with Trousseau syndrome. Serial assessment of coagulation and inflammatory biomarkers may help characterize disease dynamics and inform individualized management.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2026.1937471","type":"journal-article","created":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T13:32:11Z","timestamp":1789738331000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Immune checkpoint blockade and thrombo-inflammatory remodeling in microsatellite instability-high intrahepatic cholangiocarcinoma with Trousseau syndrome: a case report"],"prefix":"10.3389","volume":"13","author":[{"given":"XiaoXiao","family":"Sun","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, Jiaozhou Central Hospital of Qingdao","place":["Qingdao, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"XiaoTong","family":"Kuang","sequence":"additional","affiliation":[{"name":"Department of Science Education, Jiaozhou Central Hospital of Qingdao","place":["Qingdao, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ShanShan","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Jiaozhou Central Hospital of Qingdao","place":["Qingdao, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Cui","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Jiaozhou Central Hospital of Qingdao","place":["Qingdao, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Jiaozhou Central Hospital of Qingdao","place":["Qingdao, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JiGang","family":"Dong","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Jiaozhou Central Hospital of Qingdao","place":["Qingdao, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Health Management, Jiaozhou Central Hospital of Qingdao","place":["Qingdao, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1097\/HEP.0000000000001423","article-title":"Tumor microenvironment heterogeneity and progression mechanisms in intrahepatic cholangiocarcinoma: a study based on single-cell and spatial transcriptomic sequencing","volume":"83","author":"Li","year":"2026","journal-title":"Hepatology"},{"key":"B2","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s41572-022-00336-y","article-title":"Cancer-associated venous thromboembolism","volume":"8","author":"Khorana","year":"2022","journal-title":"Nat Rev Dis Primers"},{"key":"B3","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s12959-025-00719-7","article-title":"Cancer-associated venous thromboembolism: a comprehensive review","volume":"23","author":"Wan","year":"2025","journal-title":"Thromb J"},{"key":"B4","doi-asserted-by":"publisher","first-page":"6215","DOI":"10.2147\/IJGM.S372038","article-title":"Correlation of inflammation and coagulation markers with the incidence of deep vein thrombosis in cancer patients with high risk of thrombosis","volume":"15","author":"Setiawan","year":"2022","journal-title":"Int J Gen Med"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1111\/jth.14849","article-title":"Thromboinflammation and the hypercoagulability of COVID-19","volume":"18","author":"Connors","year":"2020","journal-title":"J Thromb Haemost"},{"key":"B6","doi-asserted-by":"publisher","first-page":"3801","DOI":"10.1038\/s41467-020-17670-y","article-title":"A decade of immune-checkpoint inhibitors in cancer therapy","volume":"11","author":"Robert","year":"2020","journal-title":"Nat Commun"},{"key":"B7","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1126\/science.aau0447","article-title":"Genetic diversity of tumors with mismatch repair deficiency influences anti-PD-1 immunotherapy response","volume":"364","author":"Mandal","year":"2019","journal-title":"Science"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1007\/s10637-019-00881-6","article-title":"Risk factors for cancer-associated thrombosis in patients undergoing treatment with immune checkpoint inhibitors","volume":"38","author":"Ando","year":"2020","journal-title":"Invest New Drugs"},{"key":"B9","doi-asserted-by":"publisher","first-page":"2548735","DOI":"10.1080\/16078454.2025.2548735","article-title":"Emerging molecular targets in deep vein thrombosis: from inflammation to coagulation","volume":"30","author":"Zhang","year":"2025","journal-title":"Hematology"},{"key":"B10","doi-asserted-by":"publisher","first-page":"5995","DOI":"10.3390\/ijms24065995","article-title":"Neutrophil extracellular traps and cancer: trapping our attention with their involvement in ovarian cancer","volume":"24","author":"Casta\u00f1o","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B11","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1111\/ejh.13598","article-title":"Prognostic impact and risk factors of cancer-associated thrombosis events in stage-IV cancer patients treated with immune checkpoint inhibitors","volume":"106","author":"Kewan","year":"2021","journal-title":"Eur J Haematol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.cytogfr.2025.01.001","article-title":"Interleukin-6 (IL-6)-associated tumor microenvironment remodelling and cancer immunotherapy","volume":"85","author":"Wu","year":"2025","journal-title":"Cytokine Growth Factor Rev"},{"key":"B13","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1038\/s41577-023-00856-y","article-title":"Targeting IL-6 trans-signalling: past, present and future prospects","volume":"23","author":"Rose-John","year":"2023","journal-title":"Nat Rev Immunol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1186\/s13058-019-1237-6","article-title":"Neutrophil extracellular traps in breast cancer and beyond: current perspectives on NET stimuli, thrombosis and metastasis, and clinical utility for diagnosis and treatment","volume":"21","author":"Snoderly","year":"2019","journal-title":"Breast Cancer Res"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1111\/cas.16160","article-title":"Microsatellite instability: a 2024 update","volume":"115","author":"Yamamoto","year":"2024","journal-title":"Cancer Sci"},{"key":"B16","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s12916-024-03257-7","article-title":"Genomic characterization and immunotherapy for microsatellite instability-high in cholangiocarcinoma","volume":"22","author":"Yang","year":"2024","journal-title":"BMC Med"},{"key":"B17","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1016\/j.thromres.2020.09.038","article-title":"Venous and arterial thromboembolic events with immune checkpoint inhibitors: a systematic review","volume":"196","author":"Solinas","year":"2020","journal-title":"Thromb Res"},{"key":"B18","doi-asserted-by":"publisher","first-page":"e013879","DOI":"10.1136\/jitc-2025-013879","article-title":"Synergistic effects of anticoagulants and platelet aggregation inhibitors with immune checkpoint inhibitors in cancer therapy: a comprehensive review of preclinical and clinical evidence","volume":"14","author":"K\u00f6tt","year":"2026","journal-title":"J Immunother Cancer"},{"key":"B19","doi-asserted-by":"publisher","first-page":"115159","DOI":"10.1016\/j.ejca.2024.115159","article-title":"Improved survival of advanced melanoma patients receiving immunotherapy with concomitant antithrombotic therapy - a multicenter study on 2419 patients from the prospective skin cancer registry ADOReg","volume":"214","author":"K\u00f6tt","year":"2025","journal-title":"Eur J Cancer"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1937471\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T13:32:12Z","timestamp":1789738332000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1937471\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,18]]},"references-count":19,"alternative-id":["10.3389\/fmed.2026.1937471"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1937471","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,18]]},"article-number":"1937471"}}